Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.

Cancer letters - 28 Dec 2020

Park Siyeon, Kim Tae Min, Cho Sung-Yup, Kim Soyeon, Oh Yumi, Kim Miso, Keam Bhumsuk, Kim Dong-Wan, Heo Dae Seog

Abstract excerpt

NRAS mutation is rarely observed in non-small cell lung cancer (NSCLC) patients, and there are no approved treatments for NRAS-mutant NSCLC. Here, we evaluated the effect of pan-RAF inhibitors on human NRAS-mutant NSCLC cell lines and performed high-throughput screening using human kinome small interfering (si)RNA or CRISPR/Cas9 libraries to identify new targets for combination NSCLC treatment. Our results...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cell Survival
Share to Drug Resistance, Neoplasm

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Drug Synergism

Share to GTP Phosphohydrolases

Share to High-Throughput Screening Assays

Share to Polo-Like Kinase 1

Share to Proto-Oncogene Proteins B-raf

Share to Pteridines

Source

Identifiers

PMID: 32979462
DOI: 10.1016/j.canlet.2020.09.018

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Combined blockade of polo-like kinase and pan-RAF is effective against NRAS-mutant non-small cell lung cancer cells.PMID 32979462Read ↗

Mutant NRASQ61 shares signaling similarities across various cancer types--potential implications for future therapies.Semantic proximity Read ↗

Metformin and trametinib have synergistic effects on cell viability and tumor growth in NRAS mutant cancer.Semantic proximity Read ↗

MicroRNA-708 emerges as a potential candidate to target undruggable NRAS.Semantic proximity Read ↗

Antitumor Effects of Pan-RAF Inhibitor LY3009120 Against Lung Cancer Cells Harboring Oncogenic BRAF Mutation.Semantic proximity Read ↗

Combination of pan-RAF and MEK inhibitors in NRAS mutant melanoma.Semantic proximity Read ↗

Targeting NRAS via miR-1304-5p or farnesyltransferase inhibition confers sensitivity to ALK inhibitors in ALK-mutant neuroblastoma.Semantic proximity Read ↗

The effect of PLK1 inhibitor in osimertinib resistant non-small cell lung carcinoma cells.Semantic proximity Read ↗

Kinome RNAi Screens Reveal Synergistic Targeting of MTOR and FGFR1 Pathways for Treatment of Lung Cancer and HNSCCSemantic proximity Read ↗

Inhibition and degradation of NRAS with a pan-NRAS monobody.Semantic proximity Read ↗

A phase Ib study of the combination of naporafenib with rineterkib or trametinib in patients with advanced and metastatic KRAS- or BRAF-mutant non-small cell lung cancer.Semantic proximity Read ↗

Dual targeting of MEK and PI3K effectively controls the proliferation of human EGFR-TKI resistant non-small cell lung carcinoma cell lines with different genetic backgrounds.Semantic proximity Read ↗

A screen for combination therapies in <i>BRAF/NRAS</i> wild type melanoma identifies nilotinib plus MEK inhibitor as a synergistic combinationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.